Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
American Association of Individual Investors4d
Why Atara Biotherapeutics, Inc.’s (ATRA) Stock Is Up 12.53%
Atara Biotherapeutics, Inc.’s ATRA share price has surged by 12.53%, which has investors questioning if this is right time to ...
Business Wire2d
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...
sfvbj13d
Atara Biotherapeutics Sees Its Share Price Fall
Atara Biotherapeutics experiences a plunge in share prices after the Food and Drug Administration holds up approval of a drug ...
HC Wainwright Issues Optimistic Outlook for ATRA Earnings
Equities researchers at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Atara ...
HC Wainwright Has Optimistic Outlook of ATRA Q3 Earnings
HC Wainwright increased their Q3 2025 earnings estimates for shares of Atara Biotherapeutics in a report released on Tuesday, ...
Atara to cut 50% of workforce amid FDA woes
Atara Biotherapeutics (ATRA) plans to cut around 50% of its workforce, just a little over a week after the FDA declined to ...
Investing13d
Atara stock holds Neutral rating after workforce cut
Tuesday, H.C. Wainwright maintained its Neutral stance on Atara Biotherapeutics stock (NASDAQ:ATRA), following the company's announcement of a significant workforce reduction. According to ...